Canadian Biotech Tailored Genes Secures over $1M Federal Investment to Scale Gene Therapy Production
Toronto, ON, October 21, 2025 The Government of Canada, through the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), […]
Author: Neeraj Bedi
Explore our latest insights, publications, news, and press releases — all in one place. Stay informed on breakthroughs, updates, and thought leadership from our team.
Innovative Gene Therapy Innovation Finds New Home In Vaughan – To Open 5000 Sq Ft Facility To “Advance Gene Therapy Innovation.”
Vaughan, Ontario, Date:21- May-2025 Something big is going on in Vaughan, Ontario. Biotech company Tailored Genes, has chosen the city
Tailored Genes Breaks New Ground to build Full-Service Viral vector Facility in Vaughan
In an era where speed, precision, and innovation are redefining the boundaries of science, Tailored Genes, a Toronto-Based Viral vector
Gene therapy for primary immune deficiencies: a Canadian perspective
Abstract The use of gene therapy (GT) for the treatment of primary immune deficiencies (PID) including severe combined immune deficiency
Canada’s Biotech Ecosystem is Thriving: Tailored Genes is Leading the Way
The recent announcement of AstraZeneca’s C$820 million investment in Canada is a testament to the nation’s emergence as a global
Canada’s Growing Biomanufacturing Sector: The Critical Role of Viral Vectors
Canada is rapidly emerging as a global powerhouse in biomanufacturing, with increased investment in research, training, and infrastructure. With initiatives
Gene Therapy is Changing Cancer Treatment
Traditional cancer treatments, including chemotherapy and radiation, have long been the standard of care. However, gene therapy presents a new
Big Moves Start with Bold Partners
At Tailored Genes, we believe that every scientific breakthrough starts with a partnership built on trust, precision, and bold ambition.
Capacity Crunch in Gene Therapy? Our Expansion Comes at the Perfect Time.
As global demand for gene therapy manufacturing soars, we’re seeing a growing strain on capacity, timelines, and reliability. Between the
